The proliferative potential of myeloma plasma cells manifest in the SCID-hu host
- PMID: 10552969
The proliferative potential of myeloma plasma cells manifest in the SCID-hu host
Abstract
The low proliferative activity of myeloma plasma cells prompted the notion that the clonotypic B cells that exist in the blood and bone marrow of all myeloma patients contain the proliferative myeloma cells (stem cell). We have exploited our severe combined immunodeficiency (SCID)-hu host system for primary myeloma to investigate whether myeloma plasma cells are capable of sustained proliferation. Purified CD38(++)CD45(-) plasma cells consistently grew and produced myeloma and its manifestations in SCID-hu hosts (8 of 9 experiments). In contrast, the plasma cell-depleted bone marrow cells from 6 patients did not grow or produce myeloma in SCID-hu hosts. Similarly, whereas plasma-cell containing blood cells from 4 patients grew and produced myeloma in hosts, neither the PC-depleted blood cells from 3 of the patients nor a blood specimen that did not contain plasma cells grew in SCID-hu hosts, regardless of their CD19-expressing cell contents. Also, in hosts injected with blood cells, although the myeloma cells were able to disseminate through the murine host system, they were only able to grow in the human bones within a human microenvironment and were not detectable in the murine blood or other organs. Interestingly, the circulating plasma cells appear to grow more avidly in the SCID-hu hosts than their bone marrow counterparts, suggesting that they represent a subpopulation of the plasma cells in the bone marrow. Although our studies clearly demonstrate the proliferative potential of myeloma plasma cells, they are suggestive, not conclusive, as to the existence of a preplasmacytic myeloma progenitor cell.
Similar articles
-
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.Blood. 1998 Oct 15;92(8):2908-13. Blood. 1998. PMID: 9763577
-
CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.Leukemia. 2012 Dec;26(12):2530-7. doi: 10.1038/leu.2012.140. Epub 2012 May 30. Leukemia. 2012. PMID: 22733078
-
Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.Clin Cancer Res. 2002 Oct;8(10):3198-204. Clin Cancer Res. 2002. PMID: 12374689
-
Multiple myeloma-initiating cells.Int J Hematol. 2013 Mar;97(3):306-12. doi: 10.1007/s12185-013-1293-0. Epub 2013 Feb 19. Int J Hematol. 2013. PMID: 23420183 Review.
-
The use of animal models in multiple myeloma.Morphologie. 2015 Jun;99(325):63-72. doi: 10.1016/j.morpho.2015.01.003. Epub 2015 Apr 17. Morphologie. 2015. PMID: 25898798 Review.
Cited by
-
Molecular and immunological mechanisms of clonal evolution in multiple myeloma.Front Immunol. 2023 Sep 6;14:1243997. doi: 10.3389/fimmu.2023.1243997. eCollection 2023. Front Immunol. 2023. PMID: 37744361 Free PMC article. Review.
-
Myeloma-Bone Interaction: A Vicious Cycle via TAK1-PIM2 Signaling.Cancers (Basel). 2021 Sep 3;13(17):4441. doi: 10.3390/cancers13174441. Cancers (Basel). 2021. PMID: 34503251 Free PMC article. Review.
-
An Improved Animal Model of Multiple Myeloma Bone Disease.Cancers (Basel). 2021 Aug 25;13(17):4277. doi: 10.3390/cancers13174277. Cancers (Basel). 2021. PMID: 34503090 Free PMC article.
-
Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis.Int J Med Sci. 2020 Jul 25;17(14):2063-2076. doi: 10.7150/ijms.48244. eCollection 2020. Int J Med Sci. 2020. PMID: 32922167 Free PMC article.
-
Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma.J Natl Cancer Inst. 2020 May 1;112(5):507-515. doi: 10.1093/jnci/djz159. J Natl Cancer Inst. 2020. PMID: 31406992 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous